RecruitingN/Aketamine

Ketamine in OCD: Efficacy and Effects on Stress and Cognition

Sponsored by Medical University of Vienna

NCT ID
NCT05577585
Target Enrollment
60 participants
Start Date
2022-10-01
Est. Completion
2026-06

About This Study

The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.

Conditions Studied

Obsessive-Compulsive DisorderPsychiatric Disorder

Interventions

  • Ketamine 50 MG/ML Blinded
  • Midazolam
  • Ketamine 50 MG/ML Open Label
  • Treatment as Usual (TAU)

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Primary diagnosis of obsessive-compulsive disorder
* A score of 16 or higher on the Yale-Brown Obsessive Compulsive Scale and ability to provide written informed consent
* At least one previous treatment for OCD

Exclusion Criteria Experimental Group:

* Any history of current or past psychotic disorder
* A manic episode within the preceding three years
* Current or unstable remitted substance abuse or dependence except nicotine
* Pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception
* Any current severe personality disorder except comorbid anankastic personality disorder
* Morbus Raynaud
* Inability to follow the study protocol or adhere to operational requirements
* Current and unstable suicidality
* Unstable hypertension
* Untreated hyperthyroidism
* Any unstable cardiovascular disease
* Untreated disorders severely affecting the HPA-axis (M.Addison, M.Cushing)
* Current pharmacological therapy severely affecting the HPA-axis like corticosteroids or ACTH

Exclusion Criteria Treatment as Usual Group:

* Any history of current or past psychotic disorder
* A manic episode within the preceding three years
* Current or unstable remitted substance abuse or dependence except nicotine
* Any current severe personality disorder except comorbid anankastic personality disorder
* Current and unstable suicidality

Study Locations (1)

Medical University of Vienna, Department of Psychiatry and Psychotherapy
Vienna, Vienna, Austria

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Christoph Kraus, MD PhD
CONTACT
+4314040035680christoph.kraus@muv.ac.at
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Ketamine in OCD: Efficacy and Effects on Stress and Cognition | Huxley